Edition:
United Kingdom

Enzymotec Ltd (ENZY.OQ)

ENZY.OQ on NASDAQ Stock Exchange Global Select Market

11.80USD
7:44pm GMT
Change (% chg)

$-0.05 (-0.42%)
Prev Close
$11.85
Open
$11.85
Day's High
$11.85
Day's Low
$11.80
Volume
6,837
Avg. Vol
26,918
52-wk High
$12.35
52-wk Low
$5.95

Summary

Name Age Since Current Position

Steve Dubin

60 2014 Independent Chairman of the Board

Erez Israeli

48 2017 President, Chief Executive Officer

Yoav Doppelt

48 2014 Independent Vice Chairman of the Board

Dror Israel

46 2017 Chief Financial Officer, Vice President

Yoav Kahane

42 2013 Chairman of Advanced Lipids AB

Yoni Twito

47 2009 Chief Operating Officer

Naama Zamir

43 2013 Vice President - Human Resources and Information Systems

Gai Ben-Dror

45 Vice President - Process Development

Tzafra Cohen

47 2013 Vice President - Research & Development

Tamar Howson

68 2015 Director

Holger Liepmann

63 2015 Director

Jacob Bachar

50 2011 Independent Director

Nir Belzer

51 Independent Director

Dov Pekelman

77 Independent Director

Yossi Peled

66 Independent Director

Michal Silverberg

37 2013 Independent Director

Joseph Tenne

62 2013 Independent Director

Imanuel Wasserman

47 2011 Independent Director

Katie Turner

IR Contact Officer

Biographies

Name Description

Steve Dubin

Mr. Steve Dubin is Independent Chairman of the Board of the company. He previously served as Vice Chairman since his appointment as a director in April 2013. Since November 2011, Mr. Dubin has been a Principal in SDA Ventures LLC, a firm focused on assisting emerging growth and middle-market companies, primarily in the health & wellness and nutritional products markets, on matters including corporate development, business acquisition, customer relations, growth strategies and corporate finance. In connection with SDA Ventures, Mr. Dubin acts as a Senior Advisor to Paine & Partners, LLC, a global private equity investment firm located in New York, Chicago, and San Francisco, for the purpose of identifying and executing investment opportunities in the global human and animal food and nutritional products industries. From 2006 until its acquisition by Royal DSM N.V. in February 2011, Mr. Dubin served as Chief Executive Officer and a member of the board of directors of Martek Biosciences Corporation. He later served as President of DSM’s Nutritional Lipids Division from February 2011 through October 2011 and as a Senior Advisor to DSM Nutritional Products from November 2011 through October 2012. Mr. Dubin currently serves as a member of the board of several privately held companies, including NeurExpand Brain Center LLC, formerly The Brain Center, LLC (where he serves as Vice Chair of the board of directors), MyCell Technologies and its subsidiary Oceans Omega LLC, and Alcresta, Inc. During 2011 and 2012, he was a member of the board of directors of Scerene Healthcare, Inc. Mr. Dubin holds a bachelor’s degree in accounting from the University of Maryland and a Juris Doctor degree from the National Law Center at George Washington University. He is a certified public accountant and a member of the Maryland Bar.

Erez Israeli

Mr. Erez Israeli has been appointed as President, Chief Executive Officer of the Company, effective April 18, 2017. Mr. Israeli has more than 20 years of experience in strategic planning, business processes, operation, quality, finance and global sales and marketing. Mr. Israeli was most recently the President and CEO of Growth Markets at Teva Pharmaceuticals where he oversaw all commercial activities in Asia, Asia Pacific, Africa and Latin America. Since joining Teva in 1994, he has held various leadership roles including the Head of Global Quality, President and CEO of Teva API and President, and Group Executive Vice President and Chief Business Process Officer at Teva. Mr. Israeli obtained his MBA in Finance and Marketing from Bar Ilan University, Israel.

Yoav Doppelt

Mr. Yoav Doppelt is Independent Vice Chairman of the Board of the company. He previously served as our Chairman since October 2011 and a director since 2001. Mr. Doppelt has served as the Chief Executive Officer of XT Investments Ltd. since its inception in 2007 and has held various finance and managerial positions within the XT Group (formerly known as the Ofer Group), including Chief Executive Officer of XT Hi-Tech Investments (1992) Ltd., which is an indirect wholly-owned subsidiary of XT Investments Ltd. Mr. Doppelt currently serves as a member of the board of directors of a number of companies, including Israel Corporation Ltd., TowerJazz Ltd., Lumenis Ltd., MGVS Ltd., Yozma III Management and Investments Ltd., RayV Inc. and Angioslide Ltd. Mr. Doppelt has been actively involved in numerous investments within the Israeli private equity, healthcare and technology arenas. He has extensive business experience which varies from growth companies to large conglomerates through his board membership in Israel Corporation Ltd. He holds a bachelor’s degree in economics and management from the Faculty of Industrial Management at the Technion - Israel Institute of Technology, Haifa, Israel, and an MBA degree from Haifa University, Israel. Mr. Doppelt was appointed as a director pursuant to XT Hi-Tech Investments (1992) Ltd.’s appointment rights under our articles of association in effect prior to our initial public offering.

Dror Israel

Mr. Dror Israel has been appointed as Chief Financial Officer, Vice President of the Company., effective August 7, 2017. He served as Chief Financial Officer of EZchip Semiconductor Ltd. (NASDAQ:EZCH) (TASE:EZCH) from July 2001 until February 2016, playing a key role in the sale of EZchip to Mellanox Technologies, Ltd. in February 2016. Prior to that, he was EZchips financial controller from January 2000 through May 2001 and a financial analyst at EZchip from August 1997 through December 1999. Prior to joining EZchip, Mr. Israel was employed by Hi Group, a holdings company, as a financial analyst. Mr. Israel holds a B.A. degree in economics from Haifa University and a MBA cum laude from the Technion-Israel Institute of Technology.

Yoav Kahane

Mr. Yoav Kahane serves as Chairman of our 50% owned Swedish joint venture, Advanced Lipids AB, since January 2013 and as our Director of Business Development, focused on our Infant Nutrition activities, since June 2009. Since joining Enzymotec in January 2006, Mr. Kahane has held a number of managerial positions, including Vice President of Infant Nutrition from 2006 to June 2009, Chief Executive Officer of Advanced Lipids AB from incorporation in June 2007 to June 2009, and Vice President, Sales and Marketing from June 2007 to June 2008. Prior to joining us, he served as Vice President, Sales and Marketing of Elbit Vision Systems Ltd. from 2004 to 2005 and as Manager of Business Development of Denver Holdings and Investments Ltd. from 2001 to 2002. From 1996 to 2001, Mr. Kahane held various positions with Ituran Location and Control Ltd., including Chief Executive Officer of Ituran Florida Corp from 2000 to 2001, Vice President, Operation and Customer Service from 1998 to 2000. He also served as a director of Ituran since 1998. In addition, Mr. Kahane serves as a director of two private companies, Mobydom Ltd. and Spot-On Therapeutics Ltd., and also serves as CEO of the latter. He holds a bachelor’s degree in life sciences from Tel-Aviv University, Israel, a bachelor’s degree in insurance from the Israel Academic School of Insurance (now part of the Netanya Academic College), Netanya, Israel, and an MBA from the University of Haifa, Israel.

Yoni Twito

Mr. Yoni Twito serves as Chief Operating Officer of Enzymotec Ltd. Prior thereto, Mr. Twito had been Production Manager of Enzymotec since 2003, with responsibility for planning and operating our new plant. Mr. Twito has over 20 years of experience in process and R&D engineering, production and operations. Prior to joining Enzymotec, he was a research and development engineer at Tower Semiconductor Ltd. from 2000 to 2003 and plants manager at Fertilizers and Chemicals Ltd., a subsidiary of Israel Chemicals Ltd., from 1993 to 2000. Mr. Twito has a bachelor’s degree in chemical engineering from the Technion Israel Institute of Technology, Haifa Israel, and an MBA from Haifa University, Israel.

Naama Zamir

Ms. Naama Zamir is Vice President of Human Resources and Information Systems of Enzymotec Ltd. From September 2009 to April 2013, she was our Vice President — Human Resources and Special Projects. From 2007 to 2009, Ms. Zamir served as Director of Special Projects, focusing mainly on the planning and construction of our new plant and facilities. Prior to joining Enzymotec in 2007, she served as Chief Financial Officer of Barnev Ltd., a medical device company, from 2003 to 2007. Before working at Barnev Ltd., Ms. Zamir served as a Financial Director of Privia Ltd., a global software company, from 2001 to 2003 and as Controller of Carmel Biosensors Ltd. from 2000 to 2001. She is a certified public accountant and holds an MBA from Hariot-Watt University, Edinburgh, Scotland.

Gai Ben-Dror

Mr. Gai Ben-Dror is Vice President - Process Development of Enzymotec Ltd. He previously served as Director of Process Development since joining Enzymotec in December 2001. As Director of Process Development, he was responsible for the development and commercialization of all of our products and for the building of our technological and analytical teams. Prior to joining us, Mr. Ben-Dror was a plant and pilot engineer in the Dead Sea Bromine Group of Israel Chemicals Ltd. from 1996 to 2000. Prior to that he worked as a research team leader at Sense-IT Ltd., a hardware development company, and as a project manager at Chimtec Ltd., a water treatment engineering company. He holds a bachelor’s degree in chemical engineering and an MBA from Ben-Gurion University of the Negev, Beer Sheva, Israel.

Tzafra Cohen

Dr. Tzafra Cohen joined Enzymotec Ltd in 2005 and has served as Vice President - Research and Development since October 2013. Prior to that she served as Vice President of Infant Nutrition since from 2010 to October 2013. Additionally, Dr. Cohen was Chief Executive Officer of Advanced Lipids AB, our 50% owned Swedish joint venture, from September 2010 to December 2012. From 2005 to 2010, she served as Vice President of Research and Development (R&D) and was responsible for clinical trials, regulatory affairs and intellectual property. Prior to joining Enzymotec, Dr. Cohen was Vice President, Production and Director of R&D at MGVS Ltd., a biotech company that develops cell therapy products for blood vessel disorders, from 2001 to 2004. Before working at MGVS Ltd., she was director of the pathology laboratory at the Carmel Medical Center in Haifa, Israel from 1999 to 2001 and a research associate in the vascular biology laboratory at the Technion — Israel Institute of Technology, Haifa, Israel from 1997 to 1999. Dr. Cohen holds a bachelor’s degree, a master’s degree and a Ph.D in biotechnology and food engineering from the Technion — Israel Institute of Technology, Haifa, Israel.

Tamar Howson

Ms. Tamar D. Howson is Director of Enzymotec Ltd. Tamar Howson has served as a corporate business development and strategy consultant to biopharmaceutical companies since 2011. From 2009 to 2011, she worked for JSB-Partners, a transaction advisory firm, providing business development support to life sciences companies. From 2007 to 2008, Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals. Ms. Howson also held the position of Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb from 2001 to 2007. Ms. Howson currently serves on the Board of Directors of publicly traded Organovo, Inc., OXiGENE, Inc. and Cynapsus, Inc. In the past, Ms. Howson served as a director of Actavis plc, Idenix Pharmaceuticals Inc., Warner Chilcott plc, Soligenix, Inc. and Cardax, Inc., all of which are publicly traded. In addition, Ms. Howson serves as a director of the International Partnership for Microbicides, a non-profit product development partnership. She has also served on the Boards of Aradigm, S*BIO, Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept and HBA.Ms. Howson holds a bachelor's degree in Chemical Engineering from the Technion, Israel, a MS from the City University of New York and an MBA from Columbia University.

Holger Liepmann

Mr. Holger A. Liepmann is a Director of the Company. He held various positions at Abbott Laboratories from 1986 until his retirement in 2011. From 2006 to 2011, he served as Executive Vice President, Nutritional Products of Abbott Laboratories and reported to the Chief Executive Officer. In this capacity he was responsible for all aspects of Abbott Laboratories' global nutritional business, including R&D, manufacturing, supply chain and commercial operations. He has held senior management positions in the Pharmaceutical Products Group, Abbott International, the commercial operations for Abbott's international pharmaceutical business, and Japan Operations. Prior to joining Abbott, he worked for Bayer AG in a variety of capacities between 1975 and 1986. Mr. Liepmann has enjoyed an international career with postings in Japan, Spain, Puerto Rico, Germany and the US. He earned a bachelor's degree from Dartmouth College and a master's degree in business administration from Stanford University.

Jacob Bachar

Mr. Jacob (Yaacov) Bachar is Independent Director of Enzymotec Ltd since October 2011. Mr. Bachar was the Chief Executive Officer of the Israeli Cattle Breeders Association from February 2008 to September 2013. He served on the board of directors of Galam Ltd. from 1995 until 2012. Mr. Bachar served as Chairman of the real-estate fund of the Israeli Kibbutz Movement (“HaTnua HaKibbutzit”) during the years 2004 – 2008 and as the Chairman of the Settlements Department (“Agaf Hahityashvut”) in the Israeli Ministry of Defense during 2006 – 2007. Prior to that, Mr. Bachar served as the Chief Executive Officer of Granot Central Cooperative from 1999 until 2006. Mr. Bachar was appointed as a director pursuant to Galam’s appointment rights under our articles of association in effect prior to our initial public offering.

Nir Belzer

Mr. Nir Belzer is Independent Director of Enzymotec Ltd. Mr. Belzer is a co-founder of Aquagro Fund L.P., one of Israel’s first funds to focus on clean technologies, and has served as its Managing Partner since 2007. In addition, he is a co-founder of the Millennium Materials Technologies funds, one of which is a major shareholder of ours, and has served as Managing Partner of the funds since 1998. Mr. Belzer has 20 years of extensive experience in venture capital management, including fund management in Israel’s IDB Group. From 1995 to 1997, Mr. Belzer worked in the Israeli high tech industry, at Globes — a leading Israeli financial newspaper, as a Marketing Manager, and at Israel Aerospace Industries Ltd., as an avionics engineer for the Lavi project. He holds a bachelor’s degree in mathematics and computer science, and avionics and an MBA from Tel Aviv University. Mr. Belzer was appointed as a director pursuant to Millennium Materials Technologies’ appointment rights under our articles of association in effect prior to our initial public offering.

Dov Pekelman

Prof. Dov Pekelman is Independent Director of Enzymotec Ltd. In addition, Professor Pekelman currently serves as the Chairman of the special committee of the board of directors of Taro Pharmaceuticals Industries Ltd. (NYSE: TARO), as well as Chairman of Atera Networks Ltd., Chairman of Gilon Investments (TASE: GILN), and Director of Makhteshim Agan Industries Ltd. (TASE: MAIN). He lectures at the Arison School of Business of the Interdisciplinary Center (IDC), Herzliya, Israel and serves on the board of directors of the IDC and is Chairman of the IDC Corporation, the center’s economic arm. From 1985 to 2008, Professor Pekelman served as a senior consultant to Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and also founded and ran a leading, Israeli-based management-consulting firm, P.O.C. Ltd. Previously, he served on the board of directors of several large industrial corporations, including Koor Industries Ltd. (TASE: KOR), and was also a member of the advisory committee of the Bank of Israel. He holds a doctorate from the University of Chicago and a bachelor’s degree from the Technion — Israel Institute of Technology, Haifa, Israel.

Yossi Peled

Mr. Yossi Peled is Independent Director of Enzymotec Ltd. From June 2009 to October 2011, Mr. Peled was the Chairman of our board of directors. In addition, he has served as the Chief Executive Officer of Galam Ltd. since 1987 and from 1977 until 1984. Mr. Peled is a member of the board of directors of a number of companies within the Galam Group, including Eurosweet GmbH (of which he is Chairman) and Galam Invest Ltd. From 2001 to 2003, Mr. Peled served as the Chairman of the board of directors of Lehavot Fire Protection Ltd., Israel’s leading fire protection equipment manufacturer. Previously, he held various managerial roles in Kibbutz Maanit and HaKibbutz HaArtzi, the national kibbutz organization in Israel, which represents more than 250 kibbutzim. Mr. Peled studied business administration at the Ruppin Academic Center, Israel, and executive business management at “Lahav” of the Faculty of Management Tel Aviv University. Mr. Peled was appointed as a director pursuant to Galam’s appointment rights under our articles of association in effect prior to our initial public offering.

Michal Silverberg

Ms. Michal Silverberg is Independent Director of Enzymotec Ltd since September 2013. Since 2007, Ms. Silverberg has worked in various positions in Novo Nordisk Inc., a global healthcare company headquartered in Denmark with shares listed on the Copenhagen and New York Stock Exchanges. Since 2010, she has served as Senior Director, New Product Commercialization & Business Development for the BioPharm unit. Prior to joining Novo Nordisk, Ms. Silverberg held various positions in a biotech company, an investment group and the Office of the Chief Scientist of Israel (Technological Incubators). Ms. Silverberg holds a B.A. in Economics and Business Management from Haifa University, Israel, an M.B.A. from Tel Aviv University, Israel, and an M.A. in Biotechnology from Columbia University, New York.

Joseph Tenne

Mr. Joseph Tenne is Independent Director of Enzymotec Ltd, since September 2013. Mr. Tenne has served as a director of AudioCodes Ltd., an Israeli company listed on NASDAQ and on the Tel Aviv Stock Exchange since June 2003. Mr. Tenne is a financial expert, independent director and a member of the audit, compensation and nomination committees of AudioCodes. From March 2005 until April 2013, Mr. Tenne served as the Chief Financial Officer of Ormat Technologies, Inc., a company listed on the New York Stock Exchange, which is engaged in the geothermal and recovered energy business. From January 2006 until April 2013, Mr. Tenne also served as the Chief Financial Officer of Ormat Industries Ltd., an Israeli holding company listed on the Tel Aviv Stock Exchange and the parent company of Ormat Technologies, Inc. From 2003 to 2005, Mr. Tenne was the Chief Financial Officer of Treofan Germany GmbH & Co. KG, a German company, which is engaged in the development, production and marketing of oriented polypropylene films, which are mainly used in the food packaging industry. From 1997 until 2003, Mr. Tenne was a partner in Kesselman & Kesselman, Certified Public Accountants in Israel and a member of PricewaterhouseCoopers International Limited (PwC Israel). Mr. Tenne holds a B.A. in Accounting and Economics and an M.B.A. from Tel Aviv University. Mr. Tenne is also a Certified Public Accountant in Israel.

Imanuel Wasserman

Dr. Imanuel (Mani) Wasserman is Independent Director of Enzymotec Ltd. Dr. Wasserman is a co-founder of Beresheit General Partner Ltd., the general partner of Manof I funds, a NIS 2 billion Israeli fund, and has served as its managing partner since its inception in 2009. The fund is the first and largest of three “Manof” funds, initiated by the Israeli government to provide liquidity to the Israeli economy by providing debt, mezzanine and equity financings. The Israeli government committed to invest up to NIS 0.5 billion in the fund, and the remaining commitment to invest up to NIS 1.5 billion was made by leading Israeli financial institutions. Previously he was a co-founder and managing director of Magna Capital Ltd., an Israeli strategy and M&A consulting firm, from 2000 to 2009. In addition, Dr. Wasserman worked as a lawyer, from 1992 to 1994 and from 1997 to 1999, with Zellermayer Pelossof and Co., an Israeli law firm. From 1995 to 1996, he was a foreign lawyer at Fried, Frank, Harris, Shriver and Jacobson, a U.S. law firm. Dr. Wasserman is the Chairman of Zohar Dalia, an Israeli manufacturer of cleaning products and raw materials. He currently serves as a Director for the following companies: Beresheit General Partner Ltd., Galam Ltd., Cargal Ltd., Plasto-sac Ltd., Controp Ltd. and Aeronautics Ltd. Dr. Wasserman holds a bachelor’s degree in industrial engineering, an LLB, an LLM and a doctorate in law, all from Tel Aviv University. Dr. Wasserman was appointed as a director pursuant to Galam’s appointment rights under our articles of association in effect prior to our initial public offering.

Katie Turner